Genetic variation in human drug-related genes by Schärfe, Charlotta P. I. et al.
	   1	  
Genetic variation in human drug-related genes. 
Charlotta P.I. Schärfe1,2,3, Roman Tremmel4, Matthias Schwab4,5,6, Oliver Kohlbacher2,3,7,8,9*, 
Debora S. Marks1* 
 
1 Department of Systems Biology, Harvard Medical School, Boston, 02115 Massachusetts, 
USA 
2 Center for Bioinformatics, University of Tübingen, 72076 Tübingen, Germany 
3 Applied Bioinformatics, Dept. of Computer Science, 72076 Tübingen, Germany 
4 Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany 
5 Department of Clinical Pharmacology, University Hospital Tübingen, Germany,  
6 Department of Pharmacy and Biochemistry, University of Tübingen, Tübingen, Germany 
7 Quantitative Biology Center, 72076 Tübingen, Germany 
8 Faculty of Medicine, University of Tübingen, 72076 Tübingen, Germany 
9 Biomolecular Interactions, Max Planck Institute for Developmental Biology, 72076 
Tübingen, Germany 
 
 
* Corresponding authors: 
E-mail: oliver.kohlbacher@uni-tuebingen.de, debbie@hms.harvard.edu 	    
	   2	  
Abstract 
Variability in drug efficacy and adverse effects are observed in clinical practice. While the 
extent of genetic variability in classical pharmacokinetic genes is rather well understood, the 
role of genetic variation in drug targets is typically less studied. Based on 60,706 human 
exomes from the ExAC dataset, we performed an in-depth computational analysis of the 
prevalence of functional-variants in in 806 drug-related genes, including 628 known drug 
targets. We find that most genetic variants in these genes are very rare (f < 0.1%) and thus 
likely not observed in clinical trials. Overall, however, four in five patients are likely to carry a 
functional-variant in a target for commonly prescribed drugs and many of these might alter 
drug efficacy. We further computed the likelihood of 1,236 FDA approved drugs to be affected 
by functional-variants in their targets and show that the patient-risk varies for many drugs with 
respect to geographic ancestry. A focused analysis of oncological drug targets indicates that the 
probability of a patient carrying germline variants in oncological drug targets is with 44% high 
enough to suggest that not only somatic alterations, but also germline variants carried over into 
the tumor genome should be included in therapeutic decision-making.   
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About three in five Americans aged 20 and above take prescription drugs every month1 and 
many either encounter adverse drug reactions or reduced treatment efficacy2. The strong 
genetic component of altered drug response in patients is well known3 and attributed to variants 
affecting drug pharmacokinetics (PK) and pharmacodynamics (PD)4. Methods to identify these 
genetic determinants have been developed in population stratified5-7 or individualized 
settings4,8. Particularly, the vast amount of genetic information now available has opened up the 
possibility to systematically study inter-individual differences in drug response using genome-
wide association (GWA) studies9,10. Results of these efforts have so far led to the 
pharmacogenomics labeling of 170 drugs by the Food and Drug Administration (FDA)11 and 
the establishment of pharmacogenomics screening in many large hospitals in the US12 and 
Europe13. 
However, typical pharmacogenomics GWA studies struggle with study sizes that are only large 
enough to detect common variants with an effect on the phenotype, but are unable to 
statistically pick up signals from rare variants with a functional effect9,10. Thus, data from 
recent genetic population catalogs such as the 1,000 Genomes project14 and the NHLBI Exome 
Sequencing Project (ESP) have been used to determine the spectrum of variation in 
pharmacokinetics-related genes. While classification of common and rare varies by study, 
especially variants considered to be on the rare end of the spectrum (minor allele frequency 
(minor AF) < 0.5%) were found abundantly in genes associated with drug absorption, 
distribution, metabolism, or excretion (ADME)15,16 as well as in potential drug targets17. Based 
on these surveys, it was estimated that at least 97% of individuals carry actionable high-risk 
pharmacological variants affecting drug ADME in their genome12,18. However, the role of 
genetic variation in pharmacologically established drug targets is less well studied. 
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The Exome Aggregation Consortium (ExAC)19 has aggregated data from several large 
sequencing studies comprising exome sequencing data of 60,706 individuals – nearly an order 
of magnitude larger than the public population catalogs mentioned above. Using a cohort of 
this size, it now becomes possible to study even very rare variants in drug target and ADME 
genes and to calculate the overall risk of containing a functional-variation for each patient. 
Furthermore, even though geographic ancestry is a known confounding factor for drug 
response and has been incorporated in clinical decision making in the absence of individual 
genotype data20, a comprehensive inventory of functional genetic variation in drug-associated 
genes across populations is still lacking. A cohort of the size of the ExAC catalog now allows 
determining the allele frequency of very rare variants in distinct population sub-groups and 
comparing their prevalence. 
In this study, we provide a comprehensive analysis of genetic variation predicted to result in 
altered protein function (“functional-variants”) in 806 drug-related genes including 628 drug 
targets (163 targeted by cancer-therapeutics). We further describe how this may affect the 
likelihood of 1,236 FDA approved drugs to be affected by functional-variants in their targets 
and how this likelihood varies between different populations. 
Results 
Drug-related genes show high extent of genetic variability across 60K individuals 
To explore the extent of non-synonymous genetic variation in drug-related genes in the human 
populations, we analyzed single nucleotide variants in 60,706 human individual exomes from 
ExAC19 in a set of 806 drug-related genes collated from DrugBank21 and other sources15,22 (Fig. 
1a, Supplementary Table 1). The AF distribution of non-synonymous variants in drug-related 
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genes is almost identical to that of all genes (n=17,758) and 97.5% of observed non-
synonymous variants have an allele frequency < 0.1% (sometimes termed a “rare variant”19) 
(Fig. 1b, Supplementary Fig. 1). Of note, 71% of the variants in the human exome, including 
drug-related genes have not been observed previously in public repositories such as dbSNP and 
therefore can be considered novel (Supplementary Fig. 1).  
To identify variants that are most likely to affect the gene function (“functional-variants”), we 
filtered the set of non-synonymous variants for those resulting in the loss of the protein product 
(“loss-of-function”, LoF)19, or predicted to be “damaging” by PolyPhen-223 and SIFT24. This 
resulted in 61,134 functional-variants in 806 drug-related genes (of which 767 genes included 
at least one LoF variant) and, not surprisingly, these functional-variants tend to have lower AFs 
than all other non-synonymous variants (98.7% have an allele frequency < 0.1%) (Fig. 1c). 
Nevertheless, 43% of the drug-related genes with predicted functional-variants have at least 
one functional-variant with AF ≥ 0.1%. The drug-related genes with the most frequent 
functional-variants are membrane transporter genes related to drug efflux and uptake such as 
ABCB5 (three LoF, six damaging), SLC22A1 (nine damaging), and SLC22A14 (eight 
damaging). In the clinically highly important polymorphic cytochrome P450 enzyme CYP2D6 
also eight damaging variants have been identified (Supplementary Table 2). Since the ExAC 
cohort contains an order of magnitude more individuals than previously available, it also 
allowed us to identify genes with many different functional-variants even though each variant 
may be individually rare. The ADME genes with the most functional-variants per residue 
reflect similar findings from smaller cohort studies and include the glutathione S-transferase 
sodium/bile transporter SLC10A1 (0.36 variants/residue), GSTA5 (0.31 variants/residue), and 
some cytochromes P450s such as CYP1A1 (0.30 variants/residue) and CYP2C19 (0.28 
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variants/residue)15. Furthermore, our analysis revealed drug target genes with comparable 
numbers of functional-variants per residue including the dofetilide target KCNJ12 (0.31 
variants/residue) and the target for the rheumatoid arthritis drug niflumic acid, PLA2GLB (0.30 
variants/residue) (Supplementary Table 3).  
While both metrics described above may be useful to evaluate the extent of genetic variation in 
the human population, they do not quantify the risk of an individual person in the population to 
carry functional-variants in a particular gene. In order to estimate this risk, we define a statistic, 
the “cumulative allele probability” (CAP), which captures both the number of functional-
variants and their allele frequencies per gene (Methods and Supplementary Table 2). We want 
to emphasize that the CAP score of a gene does not necessarily reflect the extent to which the 
variants change the pharmacological behavior of the drug and therefore should be regarded as a 
score solely indicating a potential pharmacogenetic risk. Amongst the genes with the highest 
CAP scores, that is the highest probability of being affected by a functional-variant, are both, 
ADME genes and drug targets. The ADME genes with the highest CAP scores include NAT2 
(81%, involved in metabolizing arylamine and hydrazine drugs), CYP2D6 (59.6%, involved in 
the metabolism of 20% of most prescribed drugs in the US25) and the transporter gene 
SLCO1B1 (26.0%, a high risk gene for simvastatin-related myopathy/rhabdomyolsis26). The 
drug target genes with comparable high CAPs scores include tyrosinase (TYR; 62.4%, targeted 
by the acne drug azelaic acid), the alpha-4 subunit of the GABAA receptor GABRA4 (53%, 
targeted by benzodiazepines) and F5 (20.1%, targeted by drotrecogin alpha which was 
withdrawn from the market due to unacceptable high number of adverse drug reactions)	  (Fig. 
2). The major proportion of the CAP score for these highest ‘risk’ genes derives from common 
genetic variants many of which have been observed previously. Nevertheless, for many genes a 
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non-negligible proportion of the score is contributed by rare functional-variants, which were 
identified through the sufficiently large cohort size (see the lines in light purple and light blue 
in Figure 2a and 2b, respectively and Supplementary Table 2). In addition, we estimate that 
more than 60% of the drug-related genes in our set are putative novel candidates for 
pharmacogenomic research, so far missing relevant information from clinical studies 
(Supplementary Fig. 2)27. 
Cancer drug target genes have many germline functional-variants. 
Especially in cancer therapy, genetic variation in drug targets has been recognized to play a 
crucial role for treatment success28,29. While some cancer drugs do not act in the tumor tissue, 
the cancer drug’s primary site of action usually is in the tumor, whose genome contains tumor-
specific somatic variants as well as a subset of patient-specific germline variants30. Information 
on somatic variants from tumor samples is thus increasingly used to enable research on drug 
design and to implement stratified or personalized cancer therapy. However, the patient’s 
germline genome is routinely masked in these tumor sequencing analysis protocols28,29 
We thus wanted to assess whether target genes of drugs used in cancer therapy contain 
germline variants in the population that may affect the drug action and may be missed by 
current tumor sequencing analysis protocols. More than 15% of the drugs in this report (193 of 
the 1,236) are used in oncology (as defined by the WHO ATC code31) and between them have 
163 gene targets. Several of these targets have high probabilities of having a functional-variant 
in the germline (Supplementary Table 2). For some of these targets the germline risk directly 
corresponds to potential altered treatment effects. This is the case for the kinase KDR (also 
known as VEGFR2) (CAP=25%), which is targeted by sorafenib and sunitib to inhibit 
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vascularization of the tumor site32. Other drug targets for cancer therapeutics with high CAP 
scores include MAP4 (60%) and TUBB1 (30%) that are targets of paclitaxel, MAP1A (42%) a 
target of estramustine, CD3G (39%) a target of muromonab and PARP1(37%) a target of 
olaparib (Fig. 2). Overall, 40 cancer drug target genes, including 34 target genes with kinase 
domains, show CAP scores >1%. For these examples, functional germline variants are only 
relevant for treatment response if the tumor genome also carries them. While there is not a 
complete overlap between both germline and tumor genome due to loss of heterozygosity and 
other alterations in carcinogenesis30, our analysis suggests that a large percentage of the 
population may contain functional-variants in cancer therapeutic targets in the germline that 
may carry over to the cancer genome and could be easily overlooked by current analysis 
protocols. 
 
Aggregating risk for functional-variants in targets by drug highlights drug candidates for 
future pharmacogenomics research 
About 70% of the FDA-approved drugs analyzed here do not have any pharmacogenomics data 
associated with them in public repositories27. However, our analysis shows that there are many 
functional-variants in their target genes (Fig. 3a). To estimate how much each drug can be 
affected by functional-variants in its target genes and to highlight possible candidates for future 
research, we computed the probability of containing a functional-variant in any number of its 
reported targets in DrugBank21 by combining the CAP scores of the drug’s target genes to a 
“drug risk probability” (short DRP, see Methods for details). For all FDA-approved drugs 
considered here (n=1,236), 43% have a DRP greater than 1% (Supplementary Table 4).  The 
DRPs are weakly correlated to the number of targets (linear regression, r2 = 0.28), leaving 
	   9	  
many drugs with few targets but higher than expected DRPs (determined by root mean square 
errors, short RMSE, of the model, red circles in Supplementary Fig. 3). For instance, one of the 
two human targets of azelaic acid, tyrosinase (TYR) is highly mutated in the population causing 
a DRP of 62.5% for this drug, which results in an RMSE of 0.34. 
Drugs with the top DRP scores are paclitaxel and docetaxel (82%), quinacrine (70%), azelaic 
acid (63%), triazolam and other benzodiazepines (>50%) (Supplementary Table 4). This means 
that any individual in the population has a probability of more than 50% to carry a functional-
variant that may affect the medication outcome of these drugs. Several of the drugs with high 
DRPs are considered “essential medicines” by the WHO33. In addition to paclitaxel and 
docetaxel, these include the opioid methadone (13.6%), the diuretic amiloride (11.7%), and the 
local anesthetic lidocaine (11.4%). For instance, the drug methadone targets the D- and M-type 
opioid receptors (OPRD1, OPRM1) and whilst some non-coding variants and a single coding 
variant (rs1799971) have previously been associated with required dose adjustments and 
treatment response, we observe another 132 functional-variants in these target genes, which 
could therefore be candidates for further testing. Since variants with predicted damaging effects 
dominate especially the rather high DRPs, we filtered the variants for only those resulting in 
LoF. Restricting to these high confidence variants, the DRP decreases below 10% and the drugs 
with the highest DRP include the anti-cancer drug marimastat (8.3%), the anti-ulcer medication 
sulfacrate (8.2%), the anti-flu drug oseltamivir (6.0%) which targets human CES1 for 
activation, and several liptins used for diabetes that inhibit DPP4 (5.6%) (Supplementary Table 
4).  
We then focused our analysis on the top 100 most prescribed medications in the US (from 
201334) which results in a list of 77 unique drug compounds for further investigation. 42% of 
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these drugs have a DRP score greater than 1% of containing a functional-variant and the 
probability of an individual carrying a functional-variant in any of the targets for these 77 top 
prescribed drugs is 81%. For some of these drugs it is already well established that there is 
some genetic component to drug response, even if the details are debated35. For instance, five 
of the top fifteen most prescribed drugs in the US are asthma drugs (budesonide, salbutamol, 
salmeterol, fluticasone, and tiotropium). Whilst each of the DPRs is not particularly high 
(ranging from 0.06% to 0.25%), their widespread prescription rate (> 100 million prescriptions 
in 2013) still results in thousands of individuals who may be affected by a functional-variant. 
Similarly, statins (e.g., atorvastatin and rosuvastatin) are prescribed to nearly one in five adults 
in the US1 and primarily target HMGCR. Due to genetic variation in this target gene statins 
have a DRP of 0.18%. This means that of the 40 million individuals who are prescribed a statin 
in the US, more than 80,000 individuals could be at risk of altered pharmacodynamics of statin 
treatment due to a functional-variant in the target HMGCR. This finding is underlined by 
previous pharmacogenetic studies showing that HMGCR is the most important polymorphic 
gene for treatment success of statins36.  
Overall, the genetic-variability of drug targets of many of the top 100 prescribed drugs has not 
been systematically annotated so far (Supplementary Fig. 4), including the Alzheimer’s drug 
memantine (DRP=7.2%), the pain-medication acetaminophen (DRP=4.7%) and the proton-
pump inhibitor esomeprazole (DRP=3.1%) that all have high DRPs. While these drugs, to our 
knowledge, do not have known associations between functional-variants in drug targets with 
drug action, clinical studies show that certain proportions of patients treated with them do not 
respond to treatment. The extent of this non-response is reflected by the number needed to 
treat, NNT37. For instance, for every one patient successfully treated for Alzheimer’s diseases 
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with memantine, between two and seven patients do not respond to treatment38 (NNT=3 to 8). 
Similarly, the NNT for acetaminophen and its indication of pain is five39 and for esomeprazole 
and reflux disease is 5440.  
Drug-related genes show geographic difference in genetic variability.  
It is known that individuals with different geographic ancestry carry genetic variants with 
different frequencies41. The six populations differentiated in ExAC are of African, South Asian, 
East Asian, Finnish, Non-Finnish European, and Admixed American (Latino) ancestry19. About 
half of all functional-variants in drug-related genes (M = 54%, SD = 15.2%) are unique to only 
one of the six populations and only 0.1% of functional-variants occur with an AF ≥ 0.1% across 
all populations. Consequently, this results in drug-related genes that have a high risk of 
functional-variants depending on geographic ancestry. 	  
For instance, using a cutoff of CAP>1%, we found that 231 drug-related genes have functional 
variants in the cohort of European ancestry compared to 298 genes with functional variants for 
the cohort of African ancestry. 
Nevertheless, 114 drug-related genes showed a CAP score above 1% in each population 
indicating that there are genes with a similar world-wide pharmacogenetic relevance. 
Not surprisingly, amongst those genes with the highest difference in CAP score between 
populations are many cytochrome P450s and phase II enzymes (Supplementary Table 5), as 
noted in previous studies of smaller population sizes22. Similarly, we observe drug target genes 
with markedly different CAP scores across populations. Among the target genes with the 
highest absolute CAP score difference are VWF (which is targeted by antihemophilic factor), 
SIRT5 (targeted by suramin for treating sleeping sickness), and the gastric lipase LIPF (targeted 
by orlistat for obesity treatment). The latter has 65 functional-variants and the most frequent 
	   12	  
variants differ especially between African and East Asian cohorts (CAP 8% vs 51%). Target 
genes with high subpopulation differences also include several targets for antineoplastic agents, 
such as the olaparib-target PARP1, for which the CAP score ranges from 10.2% in patients of 
African ancestry to 69.6% in Latino patients. While the efficacy of olaparib depends on the 
tumor genome and not the germline, the risk to carry germline-originated variants in the tumor 
should not be ignored. We also observed population differences in the nucleoside transporter 
SLC28A1. While the CAP score is 4% in Non-Finish Europeans, individuals with an East Asian 
ancestry have a risk of 60%. Interestingly, several variants in SLC28A1 have been associated 
with different outcomes in non-small cell lung cancer and breast cancer42,43 when treated with 
gemcitabine, suggesting that variant differences across the populations may be involved. 
Analysis of the DRP score reveals a population-specific risk for several drugs   
Of the 1,236 FDA approved drugs considered, 241 have more than 10% absolute difference in 
DRP scores between at least two sub-population cohorts and 24 of these have more than 30% 
DRP difference (Supplementary Table 6). Out of this subset of drugs, 11 belong to the 100 
most prescribed drugs in the US and 28 are recommended worldwide by the WHO for their 
therapeutic use, including oxcarbazepine, amobarbital and dolasetron. 312 of the 1,236 drugs 
have a high risk (DRP>1%) in all six sub-populations  (Fig. 4A, and the DRP top 20 drugs 
stratified by population are illustrated in Fig. 4B).  
Well-known differences, such as response to disulfiram (treatment for chronic alcoholism), are 
recapitulated in the data (Fig 4B). Specifically, the genetic variant E487K in the disulfiram 
target ALDH2 (rs671) is seen in the ExAC East Asian population at similarly high frequencies 
as seen in previous genetic studies44.  
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The different responses in the asthma-medication salbutamol and the blood-thinner warfarin 
have been attributed to variants in their respective drug targets, including R16G in ADRB2 
(rs1042713) for salbutamol45 and 1639G>A (rs9923231) in VKORC1 for warfarin46. Since the 
well-known response altering variants were not annotated by mutation prediction software as 
functional-variants, we did not expect to see the drugs appear high in our ranked list of risk 
differences across the populations (see discussion). Nevertheless, our analysis shows that 
salbutamol still has a high risk ratio between populations, caused by 29 variants with a 
dominant contribution from one variant separating the individuals of Finnish ancestry from 
African ancestry (rs201257377, N69S, AFFIN=0.01). To our knowledge this variant has not 
been functionally characterized or previously associated with salbutamol response. Similarly, 
we observe 19 functional-variants in the warfarin target VKORC1 that are population-specific, 
including a functional-variant observed most frequently in individuals of Non-Finnish 
European or Latino ancestry, (rs61742245, D36Y, AFNFE=0.003, AFLatino=0.001), that has been 
previously associated with predisposition for warfarin resistance47. However, 16 of the 
functional-variants may be novel risk factors including a functional-variant primarily observed 
in individuals of East Asian ancestry (R53S, ENST00000394975.2:c.157C>A, AFEAS=0.001). 
Using a recent protein 3D model48,49 of VKORC1, we mapped the R53S variant to the putative 
warfarin binding pocket (Fig. 3B). Furthermore, analysis of coevolution in the protein using 
EVfold50 shows that R53 is strongly coupled to other residues in the protein and changes in this 
site are predicted by EVmutation51 to affect protein fitness due to epistatic variant effects 
(Supplementary Fig. 5).  Together, this suggests that this mutation might be negatively 
associated to warfarin binding.  
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Triflusal, a treatment for stroke re-occurrence, targets four genes (PTGS1 (also known as Cox-
1), NOS2, NFKB1, and PDE10A) that together have more functional-variants in the African 
population than in any other population (DRPAFR=37%, Fig. 4B). This difference between 
populations is mainly due to a SNP in NOS2, which occurs in the population of African 
ancestry with higher than average frequency (rs3730017, AFAFR=19% vs AFglobal=4%) and 
while not functionally characterized, has been associated with protection against cerebral 
malaria52. In PTGS1, three functional-variants have allele frequencies above 0.1% in the cohort 
of African ancestry. The most frequent variant (rs5789, L237M, AFAFR=0.5% vs 
AFglobal=1.7%) lies on the dimer interface and has previously been associated with reduced 
metabolic activity of the enzyme53. A second variant is an indel, which is predicted to result in 
the total loss of protein function (AFAFR=0.3% vs AFglobal=0.02%). The effects of the third 
functional-variant common in the African cohort (rs139956360, E259A, AFAFR=0.2% vs 
AFglobal=0.02%) on enzyme activity or drug binding is less clear from the three-dimensional 
structure of the protein and would require further exploration. Since triflusal is prescribed for 
prophylactic use in the same way as aspirin for stroke prevention, it is clearly worth further 
investigating the effects of these observed functional-variants.  
Population differences in functional-variants for cancer drugs. 
Our results also highlight a large DRP variability of cancer drugs between the populations. 
While for many of these drugs not the germline but the tumor genome are relevant for drug 
action, germline DRPs of these drugs give an estimate of the population risk to possess 
potentially resistance-causing variants in the tumor and should be screened accordingly. For 
instance, the DRPs of taxanes (docetaxel, paclitaxel and cabazitaxel) are 30 percentage points 
higher in the cohorts of South Asian and European ancestry compared to the cohort of African 
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ancestry (DRPSAS/NFE=85% vs DRPAFR=45%) due to functional-variants in the four taxane 
targets, TUBB1, MAP2, MAP4 and MAPT. Among these are three distinct positions in TUBB1 
(Q43P/H, R307C, R359W) that occur with comparably high frequencies in the South-Asian 
population. While Q43P (AFSAS=14%) has recently been associated with decreased 
progression-free survival in urothelial cell carcinoma when treated with cabazitaxel54, less is 
known about the effects of the other two variants. Mapping the affected residues onto the three 
dimensional structure of docetaxel bound to tubulin (PDB ID: 1tub55) shows that R359 interacts 
with the drug (Fig. 3C). The effect of R307C is less obvious from structural observations as it 
does not lie very close to the binding site or the interface between the monomers in the polymer 
(R307 to K124  < 15 Å, mapped on PDB ID: 3j6g56). 
Discussion 
In this study, we analyzed the extent of functional genetic variation in drug-related genes and 
its implication for 1236 FDA-approved drugs in exome sequencing data of 60,706 individuals. 
We show that not only the risk of carrying functional-variants in ADME-related genes, but also 
in drug targets is high for an individual patient. For ADME-genes this observation is in line 
with previous studies12,15,18, but novel for drug-target genes. We observed functional-variants in 
98% of the drug-related genes and at least one high confidence LoF variant in 93% of the 
genes. The prevalence of functional-variants in drug-related genes is thus higher than 
previously shown18. When considering drug target genes for the 100 most prescribed 
medications in the US the probability of carrying at least one functional-variant is above 80% 
for each patient. Together with the high risk for clinically actionable variants in ADME genes 
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(98%12) these findings indicate that genetic variability may contribute significantly to observed 
differences in drug response between patients.  
While individualized cancer therapies often focus on the somatic variants present only in tumor 
tissue, we can show that functional germline variants, which are routinely masked out in the 
analysis of somatic variants, are common in many cancer drug targets. By excluding germline 
variants that the tumor inherited from its progenitor cell from cancer genome analysis in the 
context of therapeutic decision-making may thus result in the oversight of important 
determinants for treatment response or resistance development. To what extent the tumor 
genome varies from the germline genome, is dependent on patient and cancer type. Loss of 
heterozygosity, where the germline allele is lost in the disease progression and copy number 
alterations can indeed result in drastic changes between genetic variants observed in the normal 
tissue of  a patient and the cancer30,57. The high prevalence of variants in systemic cancer 
therapy targets, such as KDR for sorafenib, further indicates, that the germline variants of target 
genes in addition to ADME genes should be considered for clinical decision making. 
Geographic ancestry is a well-established confounding factor for drug response, but few drugs 
have been assessed in their efficacy across global populations. Even where clinical trials have 
been carried out in different populations, particularly non-European and non-Asian individuals 
remain understudied. By calculating risk probabilities for drugs and different populations, we 
showed that the frequency of functional-variants in drug-related genes varies widely across 
populations. Even for drugs where population differences in response are observed, additional 
patient groups may be at high risk of altered PD due to genetic variants in drug targets. 
Especially for drugs commonly used around the world, such as those on the WHO Essential 
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Medicines list, this could result in large numbers of patients with reduced drug efficacy in 
some, but not all, of the populations they are applied in. 
The analysis in this study relied on external data for drug variant annotation and drug-gene 
associations. Even though it was possible to estimate the burden of functional variation in drug-
related genes and quantify to which extent individual drugs may be affected, there remain 
certain limitations. First of all, even manually curated drug-target associations and 
pharmacogenomics data are susceptible to spurious annotations. For example, some subunits of 
the GABA receptors including GABRA4 are generally thought to give rise to receptors resistant 
to classic benzodiazepines such as diazepam58, but have been annotated as targets for some 
benzodiazepines. Comparison to a different, independently curated set of drug-target 
associations59 further shows that annotation of drug – target pairs does not always agree. 
Furthermore, to quantify the real risk for a drug, drug-specific ADME-gene relations should be 
incorporated into the DRP calculation. For example, optimal warfarin dosing is known to be 
dependent on variants in CYP2C9 in addition to VKORC160 and variants in the ADME-gene 
UGT1A1 are documented to contribute to different responses to the cancer drug irinotecan 
around the globe61. Unfortunately, comprehensive inclusion of ADME-genes in the DRP 
calculations is currently not possible because sufficient data for ADME-genes is lacking for 
most FDA approved drugs including the relative contribution of each enzyme. Our DRP 
estimates thus probably still underestimate the drug-specific risk of functional variation as well 
as population differences. 
The vast majority of variants in drug-related genes considered in this study has not been seen 
previously and thus lacks validated knowledge about their functional impact on drug efficacy. 
We therefore had to rely on predictions of their impact on protein function. The probabilities 
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presented are based on the assumption that the functional classification is correct and represents 
enzyme activity or drug efficacy. The relative risk between genes is based on the assumption 
that there has not been a significant bias in assessment when genes already have known 
deleterious mutations. That these assumptions are not always correct, follows from the fact that 
variant classification tools are not exact, are often trained on disease-causing variant sets only, 
have issues with circularity in the classifier training data, and fail to sub-classify mutations62. 
Especially the distinction of activating and deactivating effects could be crucial for the 
downstream effects on therapy. 
This discrepancy between observed and predicted functional-effects can be illustrated on the 
well-studied PGx variants in the anti-asthmatics target ADRB2 (R16G/rs1042713, 
Q27E/rs1042714 and T164I/rs1800888) that all are classified as benign45,63. To alleviate this 
problem, one could include additional prediction algorithms, which comes at the risk of 
reduced specificity (in some cases more than half of all non-synonymous variants were 
classified as functional15) as all currently available methods have their individual drawbacks64. 
Reliable computational classification methods for variant effects on drug response remain 
scarce due to insufficient training data 64, but may arise in the future if efforts are increased to 
create such data, for example using novel high throughput methods such as deep mutational 
scans65,66. For the present study we chose a conservative approach to variant annotation that 
requires the complete loss of the protein product – which should have a marked impact on the 
drug – or the consensus prediction of two independent prediction tools at the expense of 
missing some known variants (Fig. 3A). It is thus not unlikely that the effect of the functional-
variants is still underestimated in our study. 
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Sequencing data. The use of whole exome sequencing data comes with the intrinsic limitation 
that only variants in protein coding regions can be detected, potentially missing 
pharmacologically relevant non-coding variants67 or larger structural changes of the genome. 
Furthermore, even at low false-positive rates many called variants can be inaccurate68 and 
several pharmacologically relevant gene families – namely CYPs, HLA and UGTs – are at high 
risk for variant calling errors due to the complex genetic structure of their loci69,70. While 
members of the cytochrome P450 family have indeed been found to be problematic in short-
read sequencing22, this does not apply for most other drug-related genes15,18. To reduce the 
false-positive variant calls in our survey, we included only variants of sufficient locus coverage 
and high quality.  
Furthermore, the ExAC cohort is very large in total, but not all populations are represented 
equally19. The power to detect very rare variants thus differs by an order of magnitude between 
the individual populations (from 0.01% AF for the Finnish and East Asian populations to 
0.001% for Non-Finnish European). Due to legal restrictions in the underlying exome 
sequencing projects, sample-specific data including haplotype phase is missing also in ExAC. 
Epistatic effects of variants could thus not be investigated, even though they are known to exist. 
For example, while the single variant rs12248560 (CYP2C18*17) results in increased 
CYP2C19 activity, the combination with another variant (rs28399504) is associated with loss-
of-function of the protein (CYP2C19*4B)15. 
Implications. Many major medical institutions have started implementing genotyping 
protocols for preemptive pharmacogenetic testing71-73.  However, these usually focus on a small 
number of ADME-genes12 and often only test a subset of established actionable variants using 
microarrays74. While these arrays facilitate fast and cheap screening, we show here that the vast 
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majority of variants in drug-related genes seen in the human population is not covered. We 
further want to motivate that the number of genes with pharmacogenomic variants should 
systematically include genes implicated in drug mechanism even though only very few 
examples in such genes have yet been characterized well enough to be part of a dosing 
guideline. Furthermore, with allele frequencies below 0.1%, many functional-variants in drug-
related genes are so rare that they cannot be observed in clinical trial cohorts, but may 
contribute to adverse events or diffuse lack of efficacy post-marketing. In the future, this should 
be in all phases of clinical drug development and the effects of genetic variants in genes 
associated with PD and PK of the drug candidate should be systematically characterized. 
In conclusion, large-scale sequencing efforts can be used to identify and quantify the extent of 
genetic variation in genes relevant for drug action and metabolism. Identification of such 
variants is only the first step towards better treatment decisions. Newly identified variants of 
pharmacogenomics importance require validation and ultimately updated dosing guidelines. 
The development of quality-controlled and patient-centered software solutions to combine 
available knowledge of pharmacologically actionable variants with a patient’s genome as well 
as fast and accurate approaches (experimental and computational) to functionally classify novel 
variants will thus be of high importance for a future of personalized medicine. 
Materials and Methods 
Data selection and handling 
Known pharmacogenomics associations between drugs and genetic variants were retrieved 
from PharmGKB27. Data about drugs and drug-related genes was collated from DrugBank 521. 
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Information about drug approval status, ATC code, and details about the drug – gene 
relationship (target, pharmacological action and action type) were extracted from the xml file 
using python. We further obtained a list of the top 100 most prescribed drugs of 2013 from 
drugs.com34 and the list of WHO essential medicines by parsing the Index of the 19th WHO 
Model List of Essential Medicines33. Drugs obtained from the top 100 list and WHO essential 
medicines catalog were mapped to DrugBank compounds and those where this was not 
possible were excluded. Relations between hyaluronic acid and human gene targets as well as 
between dihydropyridines and skeletal CACNA1S were removed because the literature in the 
database entry did not support the pharmacological involvement of these pairs. We further 
removed Ethanol from the list of WHO essential medicines because it is listed as a surface 
disinfectant and thus not dependent on the patient’s cellular targets.  
Drug target genes were extracted from the drug – gene relationships in DrugBank, by filtering 
this set for only those relations with established pharmacological action flag and in which the 
gene is annotated as drug target. Based on previous studies a list of pharmacologically relevant 
cellular receptors, metabolic enzymes and nuclear receptors was obtained from to recent 
pharmacogenomics surveys15,22 and comprises the set of ADME-genes. 
Genetic variant information including variant types, allele frequencies and deleterious 
prediction scores were extracted from the ExAC VCF file (release 0.3) downloaded from the 
ExAC FTP server19. Multi-allelic variants were split using vcflib breakmulti 
(https://github.com/vcflib/vcflib) and synonymous variants were excluded. We then calculated 
for each variant the allele frequency (AF) in the full cohort as well as in each ExAC population 
separately by dividing the allele count (AC) by the allele number (AN). Following information 
about ancestry were used: AFR=African, SAS=South-Asian, EAS=East-Asian, FIN=Finnish, 
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NFE=Non-Finnish Eurpean, AMR=Admixed American/Latino. We further excluded variants 
whose loci were not observed at least once in every geographic population and in 50% of all 
possible samples (i.e., minimal allele number of 60,706). After adding unique IDs to the 
variants based on chromosome position, reference and alternative gene, we removed duplicates. 
Identifier mapping, filtering and annotation was performed using the Konstanz Information 
Miner (KNIME) workflow system75 and the Python programming language (Python Software 
Foundation, https://www.python.org/).  
Variant subsets 
To evaluate variants with functional effects in the ExAC catalog, we created a subsets of 
variants with functional effects (“functional-variants”): 1) loss-of-function variants affecting 
stop codons, splice sites and shifts in the reading frame as annotated by the Loss-Of-Function 
Transcript Effect Estimator (LOFTEE) tool76 in the ExAC VCF file, and 2) variants predicted 
to have a damaging effect on the protein as predicted unanimously by PolyPhen-2 23 (‘possibly 
damaging’ or ‘probably damaging’) and SIFT24 (‘deleterious’) as annotated in the ExAC VCF 
file. Functional-variants with allele frequencies above 0.5 were excluded from this set after 
observing that there are annotation or reference genome mapping problems. For each gene we 
calculated the fraction of common (AF >= 0.1%) and rare (AF < 0.1%) alleles.  
Computation of cumulative probabilities for drugs and their related genes 
To quantify the risk of an individual person in the population to carry functional-variants in a 
particular gene, we define the “cumulative allele probability” (CAP) statistic, which captures 
both the number of functional-variants and their allele frequencies per gene.  Formally, this 
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score is the probability for an individual to carry at least one variant allele a of the observed 
alleles A in a gene g. 
𝐶𝐴𝑃 g = 1− (1−   AF 𝑎 )!!∈!  
Two types of CAP scores were calculated, one for all functional-variants in a drug-related gene 
and one based only on LoF variants. 
 To estimate how much each drug can be affected by functional-variants in its target genes, we 
further define the drug-specific “drug risk probability” (DRP) score by combining the CAP 
scores for all drug target genes. Formally, the DRP score is defined as  
𝐷𝑅𝑃 𝐷 =   1− (1−   AF 𝑎 )!!∈!!!  ∈!   
Here G is the set of all target genes for drug D, as documented in DrugBank, and Ag the set of 
all variant alleles observed in gene g. 
Correlation analysis of the DRP scores with the number of targets was performed using linear 
regression with ordinary least squares fitting using the Python package statsmodels77 to 
compute the coefficient of determination r2. 
Statistical Analysis of population differences 
 Population comparisons for CAP and DRP scores were performed using the absolute risk 
difference (RD) metric.  
𝑅𝐷 = |𝑃 event in group 2 − 𝑃 event in group 1 | 
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The RD for a drug was calculated by subtracting the score from population with the smallest 
DRP score from the score of the population with the highest DRP. To identify for which drugs 
a population has above or below average risks (Fig. 4b), we further calculated all pairwise risk 
differences between populations from which we then computed the population-specific mean 
RDs. 
Detailed variant analyses in case studies 
Protein structures for the porcine TUBB1 homologue (PDB IDs: 1tub55, 3j6g56), ADRB2 (PDB 
ID: 2rh178), PTGS1 (PDB ID: 3n8w79) and NOS2 (PDB ID: 4nos80), were obtained from the 
Protein Data Bank. Recently published homology models for VKORC1 were downloaded from 
the supplement of the respective publications48,49. Co-evolution analysis of residues was done 
using plmc-based EVcouplings50 and based on jackhmmer81 alignments created with the 
Uniprot entries of the respective protein as queries against the Uniref100 database82 (release 
01/2017). Alignment columns with more than 70% gaps and sequences with more than 50% 
gaps were excluded from the model. Functional impact was predicted using EVmutation51 and, 
in the case of VKORC1, compared to experimental warfarin binding data49. Protein structures 
were analyzed and rendered using the UCSF Chimera package from the Computer Graphics 
Laboratory, University of California, San Francisco83. 
Statistical analysis and code availability 
Statistical analysis of the data set was performed in jupyter/IPython notebooks84 using pandas85 
and other packages of the SciPy stack86. The code used to analyze the data set and produce the 
figures will be made available on github. 
	   25	  
 
References 
1. Kantor, E. D., Rehm, C. D., Haas, J. S., Chan, A. T. & Giovannucci, E. L. Trends in Prescription Drug Use Among Adults in the 
United States From 1999-2012. JAMA 314, 1818–1830 (2015). 
2. Schork, N. J. Time for one-person trials. Nature 520, 609–611 (2015). 
3. Madian, A. G., Wheeler, H. E., Jones, R. B. & Dolan, M. E. Relating human genetic variation to variation in drug responses. Trends 
in Genetics 28, 487–495 (2012). 
4. Pirmohamed, M. Personalized Pharmacogenomics: Predicting Efficacy and Adverse Drug Reactions. Annu Rev Genomics Hum 
Genet 15, 349–370 (2014). 
5. Mette, L., Mitropoulos, K., Vozikis, A. & Patrinos, G. P. Pharmacogenomics and public health: implementing ‘populationalized’ 
medicine. Pharmacogenomics 13, 803–813 (2012). 
6. O'Donnell, P. H. & Dolan, M. E. Cancer Pharmacoethnicity: Ethnic Differences in Susceptibility to the Effects of Chemotherapy. 
Clin. Cancer Res. 15, 4806–4814 (2009). 
7. Yasuda, S. U., Zhang, L. & Huang, S. M. The Role of Ethnicity in Variability in Response to Drugs: Focus on Clinical Pharmacology 
Studies - Yasuda - 2008 - Clinical Pharmacology & Therapeutics - Wiley Online Library. Clinical Pharmacology & … (2008). 
doi:10.1002/(ISSN)1532-6535 
8. Ma, Q. & Lu, A. Y. H. Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacol Rev 63, 437–459 (2011). 
9. Motsinger-Reif, A. A. et al. Genome-Wide Association Studies in Pharmacogenomics: Successes and Lessons. Pharmacogenetics 
and genomics 23, 383–394 (2013). 
10. Daly, A. K. Genome-wide association studies in pharmacogenomics. Nature Reviews Genetics 11, 241–246 (2010). 
11. PharmGKB. Drug Labels. Available at: https://www.pharmgkb.org/view/drug-labels.do. (Accessed: 14 March 2017) 
12. Dunnenberger, H. M. et al. Preemptive Clinical Pharmacogenetics Implementation: Current programs in five United States medical 
centers. Annu. Rev. Pharmacol. Toxicol. 55, 89–106 (2015). 
13. van der Wouden, C. H. et al. Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous 
Pharmacogenomics Consortium. Clinical Pharmacology &amp; Therapeutics 101, 341–358 (2017). 
14. Consortium, T. 1. G. P. A global reference for human genetic variation. Nature 526, 68–74 (2015). 
15. Kozyra, M., Ingelman-Sundberg, M. & Lauschke, V. M. Rare genetic variants in cellular transporters, metabolic enzymes, and 
nuclear receptors can be important determinants of interindividual differences in drug response. Genetics in Medicine (2016). 
doi:10.1038/gim.2016.33 
16. Bush, W. S. et al. Genetic variation among 82 pharmacogenes: The PGRNseq data from the eMERGE network. Clinical 
Pharmacology &amp; Therapeutics 100, 160–169 (2016). 
17. Nelson, M. R. et al. An abundance of rare functional variants in 202 drug target genes sequenced in 14,002 people. Science 337, 100–
104 (2012). 
18. Wright, G. E. B., Carleton, B., Hayden, M. R. & Ross, C. J. D. The global spectrum of protein-coding pharmacogenomic diversity. 
The Pharmacogenomics Journal (2016). doi:10.1038/tpj.2016.77 
19. Lek, M. et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature 536, 285–291 (2016). 
20. Ramos, E. et al. Pharmacogenomics, ancestry and clinical decision making for global populations. The Pharmacogenomics Journal 
14, 217–222 (2014). 
21. Law, V. et al. DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res 42, D1091–7 (2014). 
22. Fujikura, K., Ingelman-Sundberg, M. & Lauschke, V. M. Genetic variation in the human cytochrome P450 supergene family. 
Pharmacogenetics and genomics 25, 584–594 (2015). 
23. Adzhubei, I. A. et al. A method and server for predicting damaging missense mutations. Nat. Methods 7, 248–249 (2010). 
24. Ng, P. C. & Henikoff, S. SIFT: predicting amino acid changes that affect protein function. (2003). 
25. Zanger, U. M. & Schwab, M. Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and 
impact of genetic variation. Pharmacology & Therapeutics 138, 103–141 (2013). 
26. Mosshammer, D., Schaeffeler, E., Schwab, M. & Moerike, K. Mechanisms and assessment of statin-related muscular adverse effects. 
Br J Clin Pharmacol 78, 454–466 (2014). 
27. Whirl-Carrillo, M. et al. Pharmacogenomics Knowledge for Personalized Medicine. Clin Pharmacol Ther 92, 414–417 (2012). 
28. Rubio-Perez, C. et al. In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals targeting opportunities. Cancer 
Cell 27, 382–396 (2015). 
29. Iorio, F. et al. A Landscape of Pharmacogenomic Interactions in Cancer. Cell 166, 740–754 (2016). 
30. Stratton, M. R., Campbell, P. J. & Futreal, P. A. The cancer genome. Nature 458, 719–724 (2009). 
31. World Health Organization. ATC - Structure and principles. (2009). Available at: http://www.fhi.no/en/hn/drug/who-collaborating-
centre-for-drug-statistics-methodology/. (Accessed: 30 January 2017) 
32. Adnane, L., Trail, P. A., Taylor, I. & Wilhelm, S. M. Sorafenib (BAY 43-9006, Nexavar (R)), a dual-action inhibitor that targets 
RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Meth. Enzymol. 407, 597–+ 
(2006). 
33. Selection, W. E. C. O. T. & Medicines, U. O. E. WHO Model List of Essential Medicines. WHO Technical Report Series (The World 
Health Organisation, 2015). 
34. Top 100 Drugs for 2013 by Units - U.S. Pharmaceutical Statistics. 
35. Blake, K. & Lima, J. Pharmacogenomics of long-acting β2-agonists. Expert Opin Drug Metab Toxicol 11, 1733–1751 (2015). 
36. Chasman, D. I. et al. Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 291, 2821–2827 (2004). 
37. Walter, S. D. Number needed to treat (NNT): estimation of a measure of clinical benefit. Statistics in Medicine 20, 3947–3962 
(2001). 
	   26	  
38. Livingston, G. & Katona, C. The place of memantine in the treatment of Alzheimer's disease: a number needed to treat analysis. Int. 
J. Geriat. Psychiatry 19, 919–925 (2004). 
39. Moore, A., Collins, S., Carroll, D., McQuay, H. & Edwards, J. Single dose paracetamol (acetaminophen), with and without codeine, 
for postoperative pain. Cochrane Database Syst Rev (1996). doi:10.1002/14651858.CD001547 
40. Gatta, L. et al. Meta-analysis: the efficacy of proton pump inhibitors for laryngeal symptoms attributed to gastro-oesophageal reflux 
disease. Aliment. Pharmacol. Ther. 25, 385–392 (2007). 
41. Henn, B. M. et al. Distance from sub-Saharan Africa predicts mutational load in diverse human genomes. Proc. Natl. Acad. Sci. 
U.S.A. 113, E440–9 (2016). 
42. Soo, R. A. et al. Distribution of gemcitabine pathway genotypes in ethnic Asians and their association with outcome in non-small cell 
lung cancer patients. Lung Cancer 63, 121–127 (2009). 
43. Wong, A. L.-A. et al. Gemcitabine and platinum pathway pharmacogenetics in Asian breast cancer patients. Cancer Genomics 
Proteomics 8, 255–259 (2011). 
44. Eng, M. Y., Luczak, S. E. & Wall, T. L. ALDH2, ADH1B, and ADH1C genotypes in Asians: a literature review. Alcohol Res Health 
30, 22–27 (2007). 
45. Litonjua, A. A. et al. Very important pharmacogene summary ADRB2. Pharmacogenetics and genomics 20, 64–69 (2010). 
46. Owen, R. P., Gong, L., Sagreiya, H., Klein, T. E. & Altman, R. B. VKORC1 pharmacogenomics summary. Pharmacogenetics and 
genomics 20, 642–644 (2010). 
47. Loebstein, R. et al. A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance. Blood 109, 2477–2480 (2007). 
48. Czogalla, K. J. et al. Warfarin and vitamin K compete for binding to Phe55 in human VKOR. Nature Structural & Molecular 
Biology 24, 77–85 (2017). 
49. Shen, G. et al. Warfarin traps human vitamin K epoxide reductase in an intermediate state during electron transfer. Nature Structural 
& Molecular Biology 24, 69–76 (2017). 
50. Marks, D. S. et al. Protein 3D Structure Computed from Evolutionary Sequence Variation. PLoS ONE 6, e28766–17 (2011). 
51. Hopf, T. A. et al. Mutation effects predicted from sequence co-variation. Nat. Biotechnol. (2017). doi:10.1038/nbt.3769 
52. Trovoada, M. de J. et al. NOS2 variants reveal a dual genetic control of nitric oxide levels, susceptibility to Plasmodium infection, 
and cerebral malaria. Infect. Immun. 82, 1287–1295 (2014). 
53. Lee, C. R. et al. Identification and functional characterization of polymorphisms in human cyclooxygenase-1 (PTGS1). 
Pharmacogenetics and genomics 17, 145–160 (2007). 
54. Duran, I. et al. SNPs associated with activity and toxicity of cabazitaxel in patients with advanced urothelial cell carcinoma. 
Pharmacogenomics 17, 463–471 (2016). 
55. Nogales, E., Wolf, S. G. & Downing, K. H. Structure of the alpha beta tubulin dimer by electron crystallography. Nature 391, 199–
203 (1998). 
56. Alushin, G. M. et al. High-resolution microtubule structures reveal the structural transitions in αβ-tubulin upon GTP hydrolysis. Cell 
157, 1117–1129 (2014). 
57. Lu, C. et al. Patterns and functional implications of rare germline variants across 12 cancer types. Nature Communications 6, (2015). 
58. Möhler, H., Fritschy, J. M. & Rudolph, U. A new benzodiazepine pharmacology. J. Pharmacol. Exp. Ther. 300, 2–8 (2002). 
59. Santos, R. et al. A comprehensive map of molecular drug targets. Nat Rev Drug Discov 16, 19–34 (2016). 
60. Johnson, J. A. et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and 
Warfarin Dosing. Clin Pharmacol Ther 90, 625–629 (2011). 
61. Maitland, M. L., DiRienzo, A. & Ratain, M. J. Interpreting Disparate Responses to Cancer Therapy: The Role of Human Population 
Genetics. Journal of Clinical Oncology 24, 2151–2157 (2016). 
62. Grimm, D. G. et al. The Evaluation of Tools Used to Predict the Impact of Missense Variants Is Hindered by Two Types of 
Circularity. Hum. Mutat. 36, 513–523 (2015). 
63. Ortega, V. E. & Meyers, D. A. Pharmacogenetics: implications of race and ethnicity on defining genetic profiles for personalized 
medicine. J. Allergy Clin. Immunol. 133, 16–26 (2014). 
64. Han, S. M. et al. Targeted Next‐Generation Sequencing for Comprehensive Genetic Profiling of Pharmacogenes. Clinical 
Pharmacology &amp; Therapeutics 101, 396–405 (2017). 
65. Fowler, D. M. & Fields, S. Deep mutational scanning: a new style of protein science. Nat. Methods 11, 801–807 (2014). 
66. Melnikov, A., Rogov, P., Wang, L., Gnirke, A. & Mikkelsen, T. S. Comprehensive mutational scanning of a kinase in vivo reveals 
substrate-dependent fitness landscapes. Nucleic Acids Res 42, –e112 (2014). 
67. Hanson, C., Cairns, J., Wang, L. & Sinha, S. Computational discovery of transcription factors associated with drug response. 
Pharmacogenomics J. 16, 573–582 (2016). 
68. Shigemizu, D. et al. A practical method to detect SNVs and indels from whole genome and exome sequencing data. Scientific 
Reports 3, 2161 (2013). 
69. Droegemoeller, B. I., Wright, G. E. B., Niehaus, D. J. H., Emsley, R. & Warnich, L. Next-generation sequencing of pharmacogenes: 
a critical analysis focusing on schizophrenia treatment. Pharmacogenetics and genomics 23, 666–674 (2013). 
70. Tourancheau, A. et al. Unravelling the transcriptomic landscape of the major phase II UDP-glucuronosyltransferase drug 
metabolizing pathway using targeted RNA sequencing. The Pharmacogenomics Journal 16, 60–70 (2016). 
71. Relling, M. V. & Evans, W. E. Pharmacogenomics in the clinic. Nature 526, 343–350 (2015). 
72. Abbasi, J. Getting Pharmacogenomics Into the Clinic. JAMA 316, 1533–1535 (2016). 
73. Drew, L. Pharmacogenetics: The right drug for you. Nature 537, S60–2 (2016). 
74. Shahandeh, A. et al. Advantages of Array-Based Technologies for Pre-Emptive Pharmacogenomics Testing. Microarrays (Basel) 5, 
12 (2016). 
75. Bertold, M. R. et al. KNIME: The Konstanz information miner. in (eds. Preisach, C., Burkhardt, H., Schmidt-Thieme, L. & Decker, 
R.) 319–326 (Springer Berlin Heidelberg, 2008). doi:10.1007/978-3-540-78246-9 
76. MacArthur, D. G. et al. A systematic survey of loss-of-function variants in human protein-coding genes. Science 335, 823–828 
(2012). 
77. Seabold, S. & Perktold, J. Statsmodels: Econometric and statistical modeling with python. in (2010). 
78. Cherezov, V. et al. High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 
318, 1258–1265 (2007). 
	   27	  
79. Sidhu, R. S., Lee, J. Y., Yuan, C. & Smith, W. L. Comparison of cyclooxygenase-1 crystal structures: cross-talk between monomers 
comprising cyclooxygenase-1 homodimers. Biochemistry 49, 7069–7079 (2010). 
80. Fischmann, T. O. et al. Structural characterization of nitric oxide synthase isoforms reveals striking active-site conservation. Nat. 
Struct. Biol. 6, 233–242 (1999). 
81. Johnson, L. S., Eddy, S. R. & Portugaly, E. Hidden Markov model speed heuristic and iterative HMM search procedure. BMC 
Bioinformatics 11, 1 (2010). 
82. Suzek, B. E. et al. UniRef clusters: a comprehensive and scalable alternative for improving sequence similarity searches. 
Bioinformatics 31, 926–932 (2015). 
83. Pettersen, E. F. et al. UCSF Chimera--a visualization system for exploratory research and analysis. Journal of Computational 
Chemistry 25, 1605–1612 (2004). 
84. Perez, F. & Granger, B. E. IPython: A System for Interactive Scientific Computing. Comput. Sci. Eng. 9, 21–29 (2007). 
85. McKinney, W. Data structures for statistical computing in python. in (2010). 
86. Jones, E., Oliphant, T. & Peterson, P. SciPy: Open source scientific tools for Python. (2001). 
 
 
Acknowledgements: 
We would like to thank Ruomu Jiang for initial help with handling genetic variation data sets, 
Benjamin Schubert, Fabian Aichler, and Ulrich Mansmann for helpful discussions about the 
statistical analysis performed in the paper and Thomas Hopf for support in using the 
EVmutation toolbox. 
Author’s contributions:  
CPS, DSM and OK designed the study, CPS analyzed the data, DSM and OK helped analyzing 
the data, RT and MS provided expertise of pharmacogenetics and genomics and contributed in 
interpretation of the data, CPS and DSM wrote the manuscript, all authors contributed to 
editing the manuscript. 
 
Funding: This work was also supported in part by the Robert Bosch Foundation, Stuttgart, 
Germany and the European Commission Horizon 2020 UPGx grant (668353). 
 
The authors declare no conflict of interest. 
Abbreviations 
AF	   	   	   allele	  frequency	  ADME	   	   	   absorption,	  distribution,	  metabolism	  and	  excretion	  
	   28	  
ExAC	   	   	   Exome	  Aggregation	  Consortium	  PD	   	   	   pharmacodynamics	  PK	   	   	   pharmacokinetics	  GWAS	   	   	   genome-­‐wide	  association	  study	  LoF	   	   	   loss-­‐of-­‐function	  RMSE	   	   	   root	  mean	  square	  error	  CAP	   	   	   cumulative	  allele	  probability	  DRP	   	   	   drug	  risk	  probability	  WHO	   	   	   World	  Health	  Organisation	  	   	  
	   29	  
	  
Figure 1. Analysis of genetic variation in drug-related genes. a) The analysis pipeline consisted of 
collation of exome data from ExAC19, identification of drug – gene relationships from DrugBank21 and 
prescription information34  followed by filtering steps and subsequent computational analysis to 
investigate drug-specific risks of pharmacogenetic alterations in patients. b) Comparison of the allele 
frequency distribution between non-synonymous variants of all human genes (n=17,758) and non-
synonymous variants in drug-related genes (n=806) collated from ExAC. c) Comparison of the allele 
frequency distribution between functional-variants as predicted by LOFTEE76, Polyphen-223 and SIFT24 
and all non-synonymous variants in the drug-related genes. 
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Figure 2. Drug-related genes with highest probability of having functional-variants.  a) Protein-
centered cumulative allele probability (CAP) scores for the 100 drug targets with highest scores (purple) 
and the contribution of CAP scores as determined from rare variants alone (light purple). a1) Top 20 
target genes with highest CAP score, a2) Examples of target genes with lower CAP scores, b) 100 
ADME-genes with highest CAP scores (blue), and the corresponding CAP score determined from rare 
variants alone (light blue). b1) Top 20 ADME-genes with highest CAP scores, b2) Examples of ADME-
genes with lower CAP scores. Bubble size corresponds to the number of functional-variants observed 
for the respective gene. 
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Figure 3. Knowledge gap between observed genetic variants in the population and documented 
pharmacogenomics data. a) Availability of documented pharmacogenetic associations for 1,236 FDA-
approved drugs in public repositories such as the PharmGKB database27 (left), is less abundant than 
functional-variants observed in the population for the drug target genes (right). b) and c) Examples of 
known and novel genetic variants (green) in the target genes of warfarin and taxanes that could affect 
drug efficacy due to effects on the binding site (ligand highlighted in purple). 
Functional-variants in targets of 1236 FDA approved drugsa
Warfarin target: VKORC1b c Docetaxel target: TUBB1
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Figure 4. Variability of drug risk probabilities across populations. a) Number of drugs with shared 
(black) or private (colored) drug risk probabilities (DRP) for functional-variants in their 
pharmacological target genes greater than 1%. DRP scores were calculated by aggregating the risk of 
functional variation across all documented pharmacological target genes of that drug. b) Drugs with 
highest (top) or lowest (bottom) mean DRP difference compared to all other populations indicating for 
which this population is at higher/lower risk of encountering functional-variation in the target for a drug 
and thus higher/lower impact on drug effect. 
 
